Sage Journals: Discover world-class research

Abstract

Background:

Multiple sclerosis (MS) is thought to be T cell mediated but the mechanisms eliciting such a dysregulated adaptative immune response remain enigmatic.

Objective:

To examine the activation profile of antigen-presenting cells (APCs) in MS.

Methods:

A total of 98 study subjects were enrolled including patients suffering from relapsing–remitting, secondary- and primary-progressive (PP) MS, other inflammatory neurological diseases, and healthy controls. Blood monocytes and B cells were stimulated using specific ligands of toll-like receptors (TLRs) or inflammasomes or Epstein–Barr virus (EBV) particles. Their activation profile was determined before or after stimulation by flow cytometry (CD40, CD80, CD83, CD86, and human leukocyte antigen–antigen D related (HLA-DR)) and Luminex assay, measuring the concentration of eight cytokines in culture supernatants. Differences among groups were assessed in a linear model framework.

Results:

We demonstrate that relapsing MS patients exhibit an increased expression of HLA-DR and CD40 ex vivo, mostly at the surface of B cells. Specific stimulations of TLR or inflammasomes enhance the expression of components of the immunological synapse and the cytokine secretion but without differences between categories of study subjects.

Conclusion:

These data suggest that the activation profile of B cells is increased in MS. However, the perception of the danger signal by B lymphocytes and monocytes does not seem to be different in MS patients as compared to control subjects.

Keywords

Multiple sclerosis B cells antigen-presenting cell activation profile cytokine secretion

Get full access to this article

View all access options for this article.

References

Compston

Coles

. Multiple sclerosis. Lancet 2008; 372: 1502–1517.

Sawcer

Hellenthal

Pirinen

. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.

Fogdell-Hahn

Ligers

Gronning

. Multiple sclerosis: A modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000; 55: 140–148.

Jilek

Schluep

Harari

. HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis. J Immunol 2012; 188: 4671–4680.

Glass

Saijo

Winner

. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140: 918–934.

Fernandez

Montalban

Comabella

. Orchestrating innate immune responses in multiple sclerosis: Molecular players. J Neuroimmunol 2010; 225: 5–12.

Palanichamy

Apeltsin

Kuo

. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med 2014; 6: 248ra106.

Blauth

Owens

Bennett

. The ins and outs of B cells in multiple sclerosis. Front Immunol 2015; 6: 565.

Rezk

Miyazaki

. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 2015; 7: 310ra166.

10.

Stern

Yaari

Vander Heiden

. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med 2014; 6: 248ra107.

11.

Genc

Dona

Reder

. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997; 99: 2664–2671.

12.

Hauser

Waubant

Arnold

. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.

13.

Meier

Giovannoni

Tzartos

. Translational mini-review series on B cell subsets in disease. B cells in multiple sclerosis: Drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system? Clin Exp Immunol 2012; 167: 1–6.

14.

Kappos

Calabresi

. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378: 1779–1787.

15.

Cross

Stark

Lauber

. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180: 63–70.

16.

Krumbholz

Derfuss

Hohlfeld

. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 2012; 8: 613–623.

17.

Chastain

Duncan

Rodgers

. The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta 2011; 1812: 265–274.

18.

Gambuzza

Licata

Palella

. Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management. J Neuroimmunol 2011; 239: 1–12.

19.

Freeman

Ting

. The pathogenic role of the inflammasome in neurodegenerative diseases. J Neurochem 2016; 136(Suppl. 1): 29–38.

20.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

21.

Jilek

Jaquiery

Hirsch

. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: A cross-sectional and longitudinal study. Lancet Neurol 2010; 9: 264–272.

22.

Jilek

Schluep

Meylan

. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008; 131: 1712–1721.

23.

Jaquiery

Jilek

Schluep

. Intrathecal immune responses to Epstein-Barr virus in early multiple sclerosis. Eur J Immunol 2010; 40: 878–887.

24.

Jilek

Mathias

Canales

. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 alpha-chain (CD11a) in MS patients. Mult Scler 2014; 20(7): 837–842.

25.

Molnarfi

Schulze-Topphoff

Weber

. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013; 210: 2921–2937.

26.

Bar-Or

Fawaz

Fan

. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67: 452–461.

27.

Barr

Shen

Brown

. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012; 209: 1001–1010.

28.

Weber

Prod’homme

Patarroyo

. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010; 68: 369–383.

29.

Parker Harp

Archambault

Sim

. B cell antigen presentation is sufficient to drive neuroinflammation in an animal model of multiple sclerosis. J Immunol 2015; 194: 5077–5084.

30.

Harp

Ireland

Davis

. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol 2010; 40: 2942–2956.

31.

Ireland

Guzman

Frohman

. B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses. J Neuroimmunol 2016; 291: 46–53.

32.

Huang

Hillert

. Systemic upregulation of CD40 and CD40 ligand mRNA expression in multiple sclerosis. Mult Scler 2000; 6: 61–65.

33.

Buck

Kroner

Rieckmann

. Analysis of the C/T(-1) single nucleotide polymorphism in the CD40 gene in multiple sclerosis. Tissue Antigens 2006; 68: 335–338.

34.

Field

Shahijanian

Schibeci

. The MS risk allele of CD40 is associated with reduced cell-membrane bound expression in antigen presenting cells: Implications for gene function. PLoS ONE 2015; 10: ee0127080.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.18 MB

0.08 MB

Increased ex vivo antigen presentation profile of B cells in multiple sclerosis

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material